Skip to main content
Erschienen in: Virchows Archiv 4/2017

10.07.2017 | Original Article

Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases

verfasst von: Fabio Facchetti, Stefano Aldo Pileri, Luisa Lorenzi, Valentina Tabanelli, Lisa Rimsza, Stefania Pittaluga, Stephan Dirnhofer, Christiane Copie-Bergman, Laurence de Leval, Andreas Rosenwald, Andrew Wotherspoon, Falko Fend

Erschienen in: Virchows Archiv | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Tumors derived from histiocytic and dendritic cells encompass a large and heterogeneous group of neoplastic and reactive conditions, and their diagnosis is challenging both for pathologists and clinicians. Diagnosis is based on morphological and phenotypical findings, but hybrid features are not uncommon. Furthermore, recent studies uncovered the molecular mechanisms driving some of these tumors, improving diagnostic adequacy, and providing the basis for effective therapeutic breakthroughs.
Sixty-seven cases were submitted to the accessory cell and histiocytic neoplasms session at the European Association of Haematopathology/Society for Hematopathology workshop 2016 held in Basel, Switzerland. The cases included histiocytic sarcomas (HS), Langerhans cell tumors (LCT), Erdheim-Chester disease, interdigitating dendritic cell sarcomas (IDCS), indeterminate dendritic cell tumors (IND-DCT), follicular dendritic cell sarcomas, and blastic plasmacytoid dendritic cell neoplasms. Rosai-Dorfman disease and, more rare, conditions such as ALK-positive histiocytosis were also submitted. These cases illustrated classical and unexpected features at morphological, phenotypical, and molecular levels, providing a valuable compendium for pathologists confronting with these tumors.
The paper summarizes the most notable features of every single group of diseases, with comments about the most challenging issues, in the attempt to provide practical indications for their recognition.
Literatur
1.
Zurück zum Zitat Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumorus, Lyon Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumorus, Lyon
2.
Zurück zum Zitat Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J, Requena-Caballero L, Jordan MB, Abdel-Wahab O, Allen CE, Charlotte F, Diamond EL, Egeler RM, Fischer A, Herrera JG, Henter JI, Janku F, Merad M, Picarsic J, Rodriguez-Galindo C, Rollins BJ, Tazi A, Vassallo R, Weiss LM (2016) Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 127:2672–2681CrossRefPubMedPubMedCentral Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J, Requena-Caballero L, Jordan MB, Abdel-Wahab O, Allen CE, Charlotte F, Diamond EL, Egeler RM, Fischer A, Herrera JG, Henter JI, Janku F, Merad M, Picarsic J, Rodriguez-Galindo C, Rollins BJ, Tazi A, Vassallo R, Weiss LM (2016) Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 127:2672–2681CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375–2390CrossRefPubMedPubMedCentral Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375–2390CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Dalia S, Jaglal M, Chervenick P, Cualing H, Sokol L (2014) Clinicopathologic characteristics and outcomes of histiocytic and dendritic cell neoplasms: the moffitt cancer center experience over the last twenty five years. Cancers (Basel) 6:2275–2295CrossRef Dalia S, Jaglal M, Chervenick P, Cualing H, Sokol L (2014) Clinicopathologic characteristics and outcomes of histiocytic and dendritic cell neoplasms: the moffitt cancer center experience over the last twenty five years. Cancers (Basel) 6:2275–2295CrossRef
5.
Zurück zum Zitat Dalia S, Shao H, Sagatys E, Cualing H, Sokol L (2014) Dendritic cell and histiocytic neoplasms: biology, diagnosis, and treatment. Cancer Control 21:290–300CrossRefPubMed Dalia S, Shao H, Sagatys E, Cualing H, Sokol L (2014) Dendritic cell and histiocytic neoplasms: biology, diagnosis, and treatment. Cancer Control 21:290–300CrossRefPubMed
6.
Zurück zum Zitat Pileri SA, Grogan TM, Harris NL, Banks P, Campo E, Chan JK, Favera RD, Delsol G, De Wolf-Peeters C, Falini B, Gascoyne RD, Gaulard P, Gatter KC, Isaacson PG, Jaffe ES, Kluin P, Knowles DM, Mason DY, Mori S, Muller-Hermelink HK, Piris MA, Ralfkiaer E, Stein H, Su IJ, Warnke RA, Weiss LM (2002) Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology 41:1–29CrossRefPubMed Pileri SA, Grogan TM, Harris NL, Banks P, Campo E, Chan JK, Favera RD, Delsol G, De Wolf-Peeters C, Falini B, Gascoyne RD, Gaulard P, Gatter KC, Isaacson PG, Jaffe ES, Kluin P, Knowles DM, Mason DY, Mori S, Muller-Hermelink HK, Piris MA, Ralfkiaer E, Stein H, Su IJ, Warnke RA, Weiss LM (2002) Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology 41:1–29CrossRefPubMed
7.
Zurück zum Zitat Takahashi E, Nakamura S (2013) Histiocytic sarcoma: an updated literature review based on the 2008 WHO classification. J Clin Exp Hematop 53:1–8CrossRefPubMed Takahashi E, Nakamura S (2013) Histiocytic sarcoma: an updated literature review based on the 2008 WHO classification. J Clin Exp Hematop 53:1–8CrossRefPubMed
8.
Zurück zum Zitat Feldman AL, Arber DA, Pittaluga S, Martinez A, Burke JS, Raffeld M, Camos M, Warnke R, Jaffe ES (2008) Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone. Blood 111:5433–5439CrossRefPubMedPubMedCentral Feldman AL, Arber DA, Pittaluga S, Martinez A, Burke JS, Raffeld M, Camos M, Warnke R, Jaffe ES (2008) Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone. Blood 111:5433–5439CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Wang E, Hutchinson CB, Huang Q, Sebastian S, Rehder C, Kanaly A, Moore J, Datto M (2010) Histiocytic sarcoma arising in indolent small B-cell lymphoma: report of two cases with molecular/genetic evidence suggestive of a ‘transdifferentiation’ during the clonal evolution. Leuk Lymphoma 51:802–812CrossRefPubMed Wang E, Hutchinson CB, Huang Q, Sebastian S, Rehder C, Kanaly A, Moore J, Datto M (2010) Histiocytic sarcoma arising in indolent small B-cell lymphoma: report of two cases with molecular/genetic evidence suggestive of a ‘transdifferentiation’ during the clonal evolution. Leuk Lymphoma 51:802–812CrossRefPubMed
10.
Zurück zum Zitat Idbaih A, Mokhtari K, Emile JF, Galanaud D, Belaid H, de Bernard S, Benameur N, Barlog VC, Psimaras D, Donadieu J, Carpentier C, Martin-Duverneuil N, Haroche J, Feuvret L, Zahr N, Delattre JY, Hoang-Xuan K (2014) Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib. Neurology 83:1478–1480CrossRefPubMed Idbaih A, Mokhtari K, Emile JF, Galanaud D, Belaid H, de Bernard S, Benameur N, Barlog VC, Psimaras D, Donadieu J, Carpentier C, Martin-Duverneuil N, Haroche J, Feuvret L, Zahr N, Delattre JY, Hoang-Xuan K (2014) Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib. Neurology 83:1478–1480CrossRefPubMed
11.
Zurück zum Zitat Xue K, Song J, Yang Y, Li Z, Wu C, Jin J, Li W (2016) PAX5 promotes pre-B cell proliferation by regulating the expression of pre-B cell receptor and its downstream signaling. Mol Immunol 73:1–9CrossRefPubMed Xue K, Song J, Yang Y, Li Z, Wu C, Jin J, Li W (2016) PAX5 promotes pre-B cell proliferation by regulating the expression of pre-B cell receptor and its downstream signaling. Mol Immunol 73:1–9CrossRefPubMed
12.
Zurück zum Zitat Gatalica Z, Bilalovic N, Palazzo JP, Bender RP, Swensen J, Millis SZ, Vranic S, Von Hoff D, Arceci RJ (2015) Disseminated histiocytoses biomarkers beyond BRAF V600E: frequent expression of PD-L1. Oncotarget 6:19819–19825CrossRefPubMedPubMedCentral Gatalica Z, Bilalovic N, Palazzo JP, Bender RP, Swensen J, Millis SZ, Vranic S, Von Hoff D, Arceci RJ (2015) Disseminated histiocytoses biomarkers beyond BRAF V600E: frequent expression of PD-L1. Oncotarget 6:19819–19825CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Balar AV, Weber JS (2017) PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol Immunother Balar AV, Weber JS (2017) PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol Immunother
15.
16.
Zurück zum Zitat Chakraborty R, Burke TM, Hampton OA, Zinn DJ, Lim KP, Abhyankar H, Scull B, Kumar V, Kakkar N, Wheeler DA, Roy A, Poulikakos PI, Merad M, McClain KL, Parsons DW, Allen CE (2016) Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood 128:2533–2537CrossRefPubMed Chakraborty R, Burke TM, Hampton OA, Zinn DJ, Lim KP, Abhyankar H, Scull B, Kumar V, Kakkar N, Wheeler DA, Roy A, Poulikakos PI, Merad M, McClain KL, Parsons DW, Allen CE (2016) Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood 128:2533–2537CrossRefPubMed
17.
Zurück zum Zitat Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, Kuo FC, Ligon AH, Stevenson KE, Kehoe SM, Garraway LA, Hahn WC, Meyerson M, Fleming MD, Rollins BJ (2010) Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 116:1919–1923CrossRefPubMedPubMedCentral Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, Kuo FC, Ligon AH, Stevenson KE, Kehoe SM, Garraway LA, Hahn WC, Meyerson M, Fleming MD, Rollins BJ (2010) Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 116:1919–1923CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Nelson DS, van Halteren A, Quispel WT, van den Bos C, Bovee JV, Patel B, Badalian-Very G, van Hummelen P, Ducar M, Lin L, MacConaill LE, Egeler RM, Rollins BJ (2015) MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis. Genes Chromosomes Cancer 54:361–368CrossRefPubMed Nelson DS, van Halteren A, Quispel WT, van den Bos C, Bovee JV, Patel B, Badalian-Very G, van Hummelen P, Ducar M, Lin L, MacConaill LE, Egeler RM, Rollins BJ (2015) MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis. Genes Chromosomes Cancer 54:361–368CrossRefPubMed
19.
Zurück zum Zitat Nelson DS, Quispel W, Badalian-Very G, van Halteren AG, van den Bos C, Bovee JV, Tian SY, Van Hummelen P, Ducar M, MacConaill LE, Egeler RM, Rollins BJ (2014) Somatic activating ARAF mutations in Langerhans cell histiocytosis. Blood 123:3152–3155CrossRefPubMed Nelson DS, Quispel W, Badalian-Very G, van Halteren AG, van den Bos C, Bovee JV, Tian SY, Van Hummelen P, Ducar M, MacConaill LE, Egeler RM, Rollins BJ (2014) Somatic activating ARAF mutations in Langerhans cell histiocytosis. Blood 123:3152–3155CrossRefPubMed
20.
Zurück zum Zitat Berres ML, Lim KP, Peters T, Price J, Takizawa H, Salmon H, Idoyaga J, Ruzo A, Lupo PJ, Hicks MJ, Shih A, Simko SJ, Abhyankar H, Chakraborty R, Leboeuf M, Beltrao M, Lira SA, Heym KM, Clausen BE, Bigley V, Collin M, Manz MG, McClain K, Merad M, Allen CE (2015) BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med 212:281CrossRefPubMedPubMedCentral Berres ML, Lim KP, Peters T, Price J, Takizawa H, Salmon H, Idoyaga J, Ruzo A, Lupo PJ, Hicks MJ, Shih A, Simko SJ, Abhyankar H, Chakraborty R, Leboeuf M, Beltrao M, Lira SA, Heym KM, Clausen BE, Bigley V, Collin M, Manz MG, McClain K, Merad M, Allen CE (2015) BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med 212:281CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Edelweiss M, Medeiros LJ, Suster S, Moran CA (2007) Lymph node involvement by Langerhans cell histiocytosis: a clinicopathologic and immunohistochemical study of 20 cases. Hum Pathol 38:1463–1469CrossRefPubMed Edelweiss M, Medeiros LJ, Suster S, Moran CA (2007) Lymph node involvement by Langerhans cell histiocytosis: a clinicopathologic and immunohistochemical study of 20 cases. Hum Pathol 38:1463–1469CrossRefPubMed
22.
Zurück zum Zitat Bechan GI, Egeler RM, Arceci RJ (2006) Biology of Langerhans cells and Langerhans cell histiocytosis. Int Rev Cytol 254:1–43CrossRefPubMed Bechan GI, Egeler RM, Arceci RJ (2006) Biology of Langerhans cells and Langerhans cell histiocytosis. Int Rev Cytol 254:1–43CrossRefPubMed
23.
Zurück zum Zitat Valladeau J, Ravel O, Dezutter-Dambuyant C, Moore K, Kleijmeer M, Liu Y, Duvert-Frances V, Vincent C, Schmitt D, Davoust J, Caux C, Lebecque S, Saeland S (2000) Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity 12:71–81CrossRefPubMed Valladeau J, Ravel O, Dezutter-Dambuyant C, Moore K, Kleijmeer M, Liu Y, Duvert-Frances V, Vincent C, Schmitt D, Davoust J, Caux C, Lebecque S, Saeland S (2000) Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity 12:71–81CrossRefPubMed
24.
Zurück zum Zitat Verdijk P, Dijkman R, Plasmeijer EI, Mulder AA, Zoutman WH, Mieke Mommaas A, Tensen CP (2005) A lack of Birbeck granules in Langerhans cells is associated with a naturally occurring point mutation in the human Langerin gene. J Invest Dermatol 124:714–717CrossRefPubMed Verdijk P, Dijkman R, Plasmeijer EI, Mulder AA, Zoutman WH, Mieke Mommaas A, Tensen CP (2005) A lack of Birbeck granules in Langerhans cells is associated with a naturally occurring point mutation in the human Langerin gene. J Invest Dermatol 124:714–717CrossRefPubMed
25.
Zurück zum Zitat Brown RA, Kwong BY, McCalmont TH, Ragsdale B, Ma L, Cheung C, Rieger KE, Arber DA, Kim J (2015) ETV3-NCOA2 in indeterminate cell histiocytosis: clonal translocation supports sui generis. Blood 126:2344–2345CrossRefPubMed Brown RA, Kwong BY, McCalmont TH, Ragsdale B, Ma L, Cheung C, Rieger KE, Arber DA, Kim J (2015) ETV3-NCOA2 in indeterminate cell histiocytosis: clonal translocation supports sui generis. Blood 126:2344–2345CrossRefPubMed
26.
Zurück zum Zitat O'Malley DP, Agrawal R, Grimm KE, Hummel J, Glazyrin A, Dim DC, Madhusudhana S, Weiss LM (2015) Evidence of BRAF V600E in indeterminate cell tumor and interdigitating dendritic cell sarcoma. Ann Diagn Pathol 19:113–116CrossRefPubMed O'Malley DP, Agrawal R, Grimm KE, Hummel J, Glazyrin A, Dim DC, Madhusudhana S, Weiss LM (2015) Evidence of BRAF V600E in indeterminate cell tumor and interdigitating dendritic cell sarcoma. Ann Diagn Pathol 19:113–116CrossRefPubMed
27.
Zurück zum Zitat Stowman AM, Mills SE, Wick MR (2016) Spindle cell melanoma and interdigitating dendritic cell sarcoma: do they represent the same process? Am J Surg Pathol 40:1270–1279CrossRefPubMed Stowman AM, Mills SE, Wick MR (2016) Spindle cell melanoma and interdigitating dendritic cell sarcoma: do they represent the same process? Am J Surg Pathol 40:1270–1279CrossRefPubMed
28.
Zurück zum Zitat Magro CM, Olson LC, Nuovo G, Solomon GJ (2017) Primary cutaneous interdigitating dendritic cell sarcoma is a morphologic and phenotypic simulator of poorly differentiated metastatic melanoma: a report of 2 cases and review of the literature. Ann Diagn Pathol Magro CM, Olson LC, Nuovo G, Solomon GJ (2017) Primary cutaneous interdigitating dendritic cell sarcoma is a morphologic and phenotypic simulator of poorly differentiated metastatic melanoma: a report of 2 cases and review of the literature. Ann Diagn Pathol
29.
Zurück zum Zitat O'Malley DP, Zuckerberg L, Smith LB, Barry TS, Gunn S, Tam W, Orazi A, Kim YS, Weiss LM (2014) The genetics of interdigitating dendritic cell sarcoma share some changes with Langerhans cell histiocytosis in select cases. Ann Diagn Pathol 18:18–20CrossRefPubMed O'Malley DP, Zuckerberg L, Smith LB, Barry TS, Gunn S, Tam W, Orazi A, Kim YS, Weiss LM (2014) The genetics of interdigitating dendritic cell sarcoma share some changes with Langerhans cell histiocytosis in select cases. Ann Diagn Pathol 18:18–20CrossRefPubMed
30.
Zurück zum Zitat Go H, Jeon YK, Huh J, Choi SJ, Choi YD, Cha HJ, Kim HJ, Park G, Min S, Kim JE (2014) Frequent detection of BRAF (V600E) mutations in histiocytic and dendritic cell neoplasms. Histopathology 65:261–272CrossRefPubMed Go H, Jeon YK, Huh J, Choi SJ, Choi YD, Cha HJ, Kim HJ, Park G, Min S, Kim JE (2014) Frequent detection of BRAF (V600E) mutations in histiocytic and dendritic cell neoplasms. Histopathology 65:261–272CrossRefPubMed
31.
Zurück zum Zitat Facchetti F, Lorenzi L (2016) Follicular dendritic cells and related sarcoma. Semin Diagn Pathol 33:159–166CrossRef Facchetti F, Lorenzi L (2016) Follicular dendritic cells and related sarcoma. Semin Diagn Pathol 33:159–166CrossRef
32.
Zurück zum Zitat Perkins SM, Shinohara ET (2013) Interdigitating and follicular dendritic cell sarcomas: a SEER analysis. Am J Clin Oncol 36:395–398CrossRefPubMed Perkins SM, Shinohara ET (2013) Interdigitating and follicular dendritic cell sarcomas: a SEER analysis. Am J Clin Oncol 36:395–398CrossRefPubMed
33.
Zurück zum Zitat Saygin C, Uzunaslan D, Ozguroglu M, Senocak M, Tuzuner N (2013) Dendritic cell sarcoma: a pooled analysis including 462 cases with presentation of our case series. Crit Rev Oncol Hematol 88:253–271CrossRefPubMed Saygin C, Uzunaslan D, Ozguroglu M, Senocak M, Tuzuner N (2013) Dendritic cell sarcoma: a pooled analysis including 462 cases with presentation of our case series. Crit Rev Oncol Hematol 88:253–271CrossRefPubMed
34.
Zurück zum Zitat Ohtake H, Yamakawa M (2013) Interdigitating dendritic cell sarcoma and follicular dendritic cell sarcoma: histopathological findings for differential diagnosis. J Clin Exp Hematop 53:179–184CrossRefPubMed Ohtake H, Yamakawa M (2013) Interdigitating dendritic cell sarcoma and follicular dendritic cell sarcoma: histopathological findings for differential diagnosis. J Clin Exp Hematop 53:179–184CrossRefPubMed
35.
Zurück zum Zitat Lorenzi L, Lonardi S, Petrilli G, Tanda F, Bella M, Laurino L, Rossi G, Facchetti F (2012) Folliculocentric B-cell-rich follicular dendritic cells sarcoma: a hitherto unreported morphological variant mimicking lymphoproliferative disorders. Hum Pathol 43:209–215CrossRefPubMed Lorenzi L, Lonardi S, Petrilli G, Tanda F, Bella M, Laurino L, Rossi G, Facchetti F (2012) Folliculocentric B-cell-rich follicular dendritic cells sarcoma: a hitherto unreported morphological variant mimicking lymphoproliferative disorders. Hum Pathol 43:209–215CrossRefPubMed
36.
Zurück zum Zitat Vermi W, Lonardi S, Bosisio D, Uguccioni M, Danelon G, Pileri S, Fletcher C, Sozzani S, Zorzi F, Arrigoni G, Doglioni C, Ponzoni M, Facchetti F (2008) Identification of CXCL13 as a new marker for follicular dendritic cell sarcoma. J Pathol 216:356–364CrossRefPubMed Vermi W, Lonardi S, Bosisio D, Uguccioni M, Danelon G, Pileri S, Fletcher C, Sozzani S, Zorzi F, Arrigoni G, Doglioni C, Ponzoni M, Facchetti F (2008) Identification of CXCL13 as a new marker for follicular dendritic cell sarcoma. J Pathol 216:356–364CrossRefPubMed
37.
Zurück zum Zitat Chen W, Lau SK, Fong D, Wang J, Wang E, Arber DA, Weiss LM, Huang Q (2009) High frequency of clonal immunoglobulin receptor gene rearrangements in sporadic histiocytic/dendritic cell sarcomas. Am J Surg Pathol 33:863–873CrossRefPubMed Chen W, Lau SK, Fong D, Wang J, Wang E, Arber DA, Weiss LM, Huang Q (2009) High frequency of clonal immunoglobulin receptor gene rearrangements in sporadic histiocytic/dendritic cell sarcomas. Am J Surg Pathol 33:863–873CrossRefPubMed
38.
Zurück zum Zitat Griffin GK, Sholl LM, Lindeman NI, Fletcher CD, Hornick JL (2016) Targeted genomic sequencing of follicular dendritic cell sarcoma reveals recurrent alterations in NF-kappaB regulatory genes. Mod Pathol 29:67–74CrossRefPubMed Griffin GK, Sholl LM, Lindeman NI, Fletcher CD, Hornick JL (2016) Targeted genomic sequencing of follicular dendritic cell sarcoma reveals recurrent alterations in NF-kappaB regulatory genes. Mod Pathol 29:67–74CrossRefPubMed
39.
Zurück zum Zitat Hartmann S, Doring C, Agostinelli C, Portscher-Kim SJ, Lonardi S, Lorenzi L, Fuligni F, Martinez D, Mehta J, Borges A, Hackstein H, Kippenberger S, Piccaluga PP, Simonitsch-Klupp I, Cabecadas J, Campo E, Facchetti F, Pileri SA, Hansmann ML (2016) miRNA expression profiling divides follicular dendritic cell sarcomas into two groups, related to fibroblasts and myopericytomas or Castleman’s disease. Eur J Cancer 64:159–166CrossRefPubMed Hartmann S, Doring C, Agostinelli C, Portscher-Kim SJ, Lonardi S, Lorenzi L, Fuligni F, Martinez D, Mehta J, Borges A, Hackstein H, Kippenberger S, Piccaluga PP, Simonitsch-Klupp I, Cabecadas J, Campo E, Facchetti F, Pileri SA, Hansmann ML (2016) miRNA expression profiling divides follicular dendritic cell sarcomas into two groups, related to fibroblasts and myopericytomas or Castleman’s disease. Eur J Cancer 64:159–166CrossRefPubMed
40.
Zurück zum Zitat Laginestra MA, Tripodo C, Agostinelli C, Motta G, Hartmann S, Doring C, Rossi M, Melle F, Sapienza MR, Tabanelli V, Pileri A, Fuligni F, Gazzola A, Mannu C, Sagramoso CA, Lonardi S, Lorenzi L, Bacci F, Sabattini E, Borges A, Simonitsch-Klupp I, Cabecadas J, Campo E, Rosai J, Hansmann ML, Facchetti F, Pileri SA (2017) Distinctive histogenesis and immunological microenvironment based on transcriptional profiles of follicular dendritic cell sarcomas. Mol Cancer Res Laginestra MA, Tripodo C, Agostinelli C, Motta G, Hartmann S, Doring C, Rossi M, Melle F, Sapienza MR, Tabanelli V, Pileri A, Fuligni F, Gazzola A, Mannu C, Sagramoso CA, Lonardi S, Lorenzi L, Bacci F, Sabattini E, Borges A, Simonitsch-Klupp I, Cabecadas J, Campo E, Rosai J, Hansmann ML, Facchetti F, Pileri SA (2017) Distinctive histogenesis and immunological microenvironment based on transcriptional profiles of follicular dendritic cell sarcomas. Mol Cancer Res
41.
Zurück zum Zitat Lorenzi L, Doring C, Rausch T, Benes V, Lonardi S, Bugatti M, Campo E, Cabecadas J, Simonitsch-Klupp I, Borges A, Mehta J, Agostinelli C, Pileri SA, Facchetti F, Hansmann ML, Hartmann S (2017) Identification of novel follicular dendritic cell sarcoma markers, FDCSP and SRGN, by whole transcriptome sequencing. Oncotarget Lorenzi L, Doring C, Rausch T, Benes V, Lonardi S, Bugatti M, Campo E, Cabecadas J, Simonitsch-Klupp I, Borges A, Mehta J, Agostinelli C, Pileri SA, Facchetti F, Hansmann ML, Hartmann S (2017) Identification of novel follicular dendritic cell sarcoma markers, FDCSP and SRGN, by whole transcriptome sequencing. Oncotarget
42.
Zurück zum Zitat Rezk SA, Nathwani BN, Zhao X, Weiss LM (2013) Follicular dendritic cells: origin, function, and different disease-associated patterns. Hum Pathol 44:937–950CrossRefPubMed Rezk SA, Nathwani BN, Zhao X, Weiss LM (2013) Follicular dendritic cells: origin, function, and different disease-associated patterns. Hum Pathol 44:937–950CrossRefPubMed
43.
Zurück zum Zitat Kawabata H, Takai K, Kojima M, Nakamura N, Aoki S, Nakamura S, Kinoshita T, Masaki Y (2013) Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop 53:57–61CrossRefPubMed Kawabata H, Takai K, Kojima M, Nakamura N, Aoki S, Nakamura S, Kinoshita T, Masaki Y (2013) Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop 53:57–61CrossRefPubMed
44.
Zurück zum Zitat Zinzani PL, Corradini P, Gianni AM, Federico M, Santoro A, Vitolo U, Barosi G, Tura S (2015) Brentuximab vedotin in CD30-positive lymphomas: a SIE, SIES, and GITMO position paper. Clin Lymphoma Myeloma Leuk 15:507–513CrossRefPubMed Zinzani PL, Corradini P, Gianni AM, Federico M, Santoro A, Vitolo U, Barosi G, Tura S (2015) Brentuximab vedotin in CD30-positive lymphomas: a SIE, SIES, and GITMO position paper. Clin Lymphoma Myeloma Leuk 15:507–513CrossRefPubMed
45.
Zurück zum Zitat Emile JF, Diamond EL, Helias-Rodzewicz Z, Cohen-Aubart F, Charlotte F, Hyman DM, Kim E, Rampal R, Patel M, Ganzel C, Aumann S, Faucher G, Le Gall C, Leroy K, Colombat M, Kahn JE, Trad S, Nizard P, Donadieu J, Taly V, Amoura Z, Abdel-Wahab O, Haroche J (2014) Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood 124:3016–3019CrossRefPubMedPubMedCentral Emile JF, Diamond EL, Helias-Rodzewicz Z, Cohen-Aubart F, Charlotte F, Hyman DM, Kim E, Rampal R, Patel M, Ganzel C, Aumann S, Faucher G, Le Gall C, Leroy K, Colombat M, Kahn JE, Trad S, Nizard P, Donadieu J, Taly V, Amoura Z, Abdel-Wahab O, Haroche J (2014) Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood 124:3016–3019CrossRefPubMedPubMedCentral
46.
Zurück zum Zitat Diamond EL, Durham BH, Haroche J, Yao Z, Ma J, Parikh SA, Wang Z, Choi J, Kim E, Cohen-Aubart F, Lee SC, Gao Y, Micol JB, Campbell P, Walsh MP, Sylvester B, Dolgalev I, Aminova O, Heguy A, Zappile P, Nakitandwe J, Ganzel C, Dalton JD, Ellison DW, Estrada-Veras J, Lacouture M, Gahl WA, Stephens PJ, Miller VA, Ross JS, Ali SM, Briggs SR, Fasan O, Block J, Heritier S, Donadieu J, Solit DB, Hyman DM, Baselga J, Janku F, Taylor BS, Park CY, Amoura Z, Dogan A, Emile JF, Rosen N, Gruber TA, Abdel-Wahab O (2016) Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov 6:154–165CrossRefPubMed Diamond EL, Durham BH, Haroche J, Yao Z, Ma J, Parikh SA, Wang Z, Choi J, Kim E, Cohen-Aubart F, Lee SC, Gao Y, Micol JB, Campbell P, Walsh MP, Sylvester B, Dolgalev I, Aminova O, Heguy A, Zappile P, Nakitandwe J, Ganzel C, Dalton JD, Ellison DW, Estrada-Veras J, Lacouture M, Gahl WA, Stephens PJ, Miller VA, Ross JS, Ali SM, Briggs SR, Fasan O, Block J, Heritier S, Donadieu J, Solit DB, Hyman DM, Baselga J, Janku F, Taylor BS, Park CY, Amoura Z, Dogan A, Emile JF, Rosen N, Gruber TA, Abdel-Wahab O (2016) Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov 6:154–165CrossRefPubMed
47.
Zurück zum Zitat Estrada-Veras JI, O’Brien KJ, Boyd LC, Dave RH, Durham BH, Xi L, Malayeri AA, Chen MJ, Gardner PJ, Alvarado Enriquez JR, Shah N, Abdel-Wahab O, Gochuico BR, Raffeld M, Jaffe ES, Gahl WA (2017) The clinical spectrum of Erdheim-Chester disease: an observational cohort study. Blood Adv 1:357–366CrossRefPubMedPubMedCentral Estrada-Veras JI, O’Brien KJ, Boyd LC, Dave RH, Durham BH, Xi L, Malayeri AA, Chen MJ, Gardner PJ, Alvarado Enriquez JR, Shah N, Abdel-Wahab O, Gochuico BR, Raffeld M, Jaffe ES, Gahl WA (2017) The clinical spectrum of Erdheim-Chester disease: an observational cohort study. Blood Adv 1:357–366CrossRefPubMedPubMedCentral
48.
Zurück zum Zitat Mills JA, Gonzalez RG, Jaffe R (2008) Case records of the Massachusetts General Hospital. Case 25-2008. A 43-year-old man with fatigue and lesions in the pituitary and cerebellum. N Engl J Med 359:736–747CrossRefPubMed Mills JA, Gonzalez RG, Jaffe R (2008) Case records of the Massachusetts General Hospital. Case 25-2008. A 43-year-old man with fatigue and lesions in the pituitary and cerebellum. N Engl J Med 359:736–747CrossRefPubMed
49.
Zurück zum Zitat Paulli M, Bergamaschi G, Tonon L, Viglio A, Rosso R, Facchetti F, Geerts ML, Magrini U, Cazzola M (1995) Evidence for a polyclonal nature of the cell infiltrate in sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). Br J Haematol 91:415–418CrossRefPubMed Paulli M, Bergamaschi G, Tonon L, Viglio A, Rosso R, Facchetti F, Geerts ML, Magrini U, Cazzola M (1995) Evidence for a polyclonal nature of the cell infiltrate in sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). Br J Haematol 91:415–418CrossRefPubMed
50.
Zurück zum Zitat Shanmugam V, Margolskee E, Kluk M, Giorgadze T, Orazi A (2016) Rosai-Dorfman disease harboring an activating KRAS K117N missense mutation. Head Neck Pathol 10:394–399CrossRefPubMedPubMedCentral Shanmugam V, Margolskee E, Kluk M, Giorgadze T, Orazi A (2016) Rosai-Dorfman disease harboring an activating KRAS K117N missense mutation. Head Neck Pathol 10:394–399CrossRefPubMedPubMedCentral
51.
Zurück zum Zitat Morgan NV, Morris MR, Cangul H, Gleeson D, Straatman-Iwanowska A, Davies N, Keenan S, Pasha S, Rahman F, Gentle D, Vreeswijk MP, Devilee P, Knowles MA, Ceylaner S, Trembath RC, Dalence C, Kismet E, Koseoglu V, Rossbach HC, Gissen P, Tannahill D, Maher ER (2010) Mutations in SLC29A3, encoding an equilibrative nucleoside transporter ENT3, cause a familial histiocytosis syndrome (Faisalabad histiocytosis) and familial Rosai-Dorfman disease. PLoS Genet 6:e1000833CrossRefPubMedPubMedCentral Morgan NV, Morris MR, Cangul H, Gleeson D, Straatman-Iwanowska A, Davies N, Keenan S, Pasha S, Rahman F, Gentle D, Vreeswijk MP, Devilee P, Knowles MA, Ceylaner S, Trembath RC, Dalence C, Kismet E, Koseoglu V, Rossbach HC, Gissen P, Tannahill D, Maher ER (2010) Mutations in SLC29A3, encoding an equilibrative nucleoside transporter ENT3, cause a familial histiocytosis syndrome (Faisalabad histiocytosis) and familial Rosai-Dorfman disease. PLoS Genet 6:e1000833CrossRefPubMedPubMedCentral
52.
Zurück zum Zitat Maric I, Pittaluga S, Dale JK, Niemela JE, Delsol G, Diment J, Rosai J, Raffeld M, Puck JM, Straus SE, Jaffe ES (2005) Histologic features of sinus histiocytosis with massive lymphadenopathy in patients with autoimmune lymphoproliferative syndrome. Am J Surg Pathol 29:903–911CrossRefPubMed Maric I, Pittaluga S, Dale JK, Niemela JE, Delsol G, Diment J, Rosai J, Raffeld M, Puck JM, Straus SE, Jaffe ES (2005) Histologic features of sinus histiocytosis with massive lymphadenopathy in patients with autoimmune lymphoproliferative syndrome. Am J Surg Pathol 29:903–911CrossRefPubMed
53.
Zurück zum Zitat Chan JK, Lamant L, Algar E, Delsol G, Tsang WY, Lee KC, Tiedemann K, Chow CW (2008) ALK+ histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy. Blood 112:2965–2968CrossRefPubMed Chan JK, Lamant L, Algar E, Delsol G, Tsang WY, Lee KC, Tiedemann K, Chow CW (2008) ALK+ histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy. Blood 112:2965–2968CrossRefPubMed
54.
Zurück zum Zitat Facchetti F, Cigognetti M, Fisogni S, Rossi G, Lonardi S, Vermi W (2016) Neoplasms derived from plasmacytoid dendritic cells. Mod Pathol 29:98–111CrossRefPubMed Facchetti F, Cigognetti M, Fisogni S, Rossi G, Lonardi S, Vermi W (2016) Neoplasms derived from plasmacytoid dendritic cells. Mod Pathol 29:98–111CrossRefPubMed
55.
Zurück zum Zitat Sangle NA, Schmidt RL, Patel JL, Medeiros LJ, Agarwal AM, Perkins SL, Salama ME (2014) Optimized immunohistochemical panel to differentiate myeloid sarcoma from blastic plasmacytoid dendritic cell neoplasm. Mod Pathol 27:1137–1143CrossRefPubMed Sangle NA, Schmidt RL, Patel JL, Medeiros LJ, Agarwal AM, Perkins SL, Salama ME (2014) Optimized immunohistochemical panel to differentiate myeloid sarcoma from blastic plasmacytoid dendritic cell neoplasm. Mod Pathol 27:1137–1143CrossRefPubMed
56.
Zurück zum Zitat Cronin DM, George TI, Reichard KK, Sundram UN (2012) Immunophenotypic analysis of myeloperoxidase-negative leukemia cutis and blastic plasmacytoid dendritic cell neoplasm. Am J Clin Pathol 137:367–376CrossRefPubMed Cronin DM, George TI, Reichard KK, Sundram UN (2012) Immunophenotypic analysis of myeloperoxidase-negative leukemia cutis and blastic plasmacytoid dendritic cell neoplasm. Am J Clin Pathol 137:367–376CrossRefPubMed
57.
Zurück zum Zitat Julia F, Dalle S, Duru G, Balme B, Vergier B, Ortonne N, Vignon-Pennamen MD, Costes-Martineau V, Lamant L, Dalac S, Delattre C, Dechelotte P, Courville P, Carlotti A, De Muret A, Fraitag S, Levy A, Mitchell A, Petrella T (2014) Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients. Am J Surg Pathol 38:673–680CrossRefPubMed Julia F, Dalle S, Duru G, Balme B, Vergier B, Ortonne N, Vignon-Pennamen MD, Costes-Martineau V, Lamant L, Dalac S, Delattre C, Dechelotte P, Courville P, Carlotti A, De Muret A, Fraitag S, Levy A, Mitchell A, Petrella T (2014) Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients. Am J Surg Pathol 38:673–680CrossRefPubMed
58.
Zurück zum Zitat Ceribelli M, Hou ZE, Kelly PN, Huang DW, Wright G, Ganapathi K, Evbuomwan MO, Pittaluga S, Shaffer AL, Marcucci G, Forman SJ, Xiao W, Guha R, Zhang X, Ferrer M, Chaperot L, Plumas J, Jaffe ES, Thomas CJ, Reizis B, Staudt LM (2016) A druggable TCF4- and BRD4-dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm. Cancer Cell 30:764–778CrossRefPubMed Ceribelli M, Hou ZE, Kelly PN, Huang DW, Wright G, Ganapathi K, Evbuomwan MO, Pittaluga S, Shaffer AL, Marcucci G, Forman SJ, Xiao W, Guha R, Zhang X, Ferrer M, Chaperot L, Plumas J, Jaffe ES, Thomas CJ, Reizis B, Staudt LM (2016) A druggable TCF4- and BRD4-dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm. Cancer Cell 30:764–778CrossRefPubMed
59.
Zurück zum Zitat Jardin F, Ruminy P, Parmentier F, Troussard X, Vaida I, Stamatoullas A, Lepretre S, Penther D, Duval AB, Picquenot JM, Courville P, Capiod JC, Tilly H, Bastard C, Marolleau JP (2011) TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm. Br J Haematol 153:413–416CrossRefPubMed Jardin F, Ruminy P, Parmentier F, Troussard X, Vaida I, Stamatoullas A, Lepretre S, Penther D, Duval AB, Picquenot JM, Courville P, Capiod JC, Tilly H, Bastard C, Marolleau JP (2011) TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm. Br J Haematol 153:413–416CrossRefPubMed
60.
Zurück zum Zitat Alayed K, Patel KP, Konoplev S, Singh RR, Routbort MJ, Reddy N, Pemmaraju N, Zhang L, Shaikh AA, Aladily TN, Jain N, Luthra R, Medeiros LJ, Khoury JD (2013) TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol 88:1055–1061CrossRefPubMed Alayed K, Patel KP, Konoplev S, Singh RR, Routbort MJ, Reddy N, Pemmaraju N, Zhang L, Shaikh AA, Aladily TN, Jain N, Luthra R, Medeiros LJ, Khoury JD (2013) TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol 88:1055–1061CrossRefPubMed
61.
Zurück zum Zitat Menezes J, Acquadro F, Wiseman M, Gomez-Lopez G, Salgado RN, Talavera-Casanas JG, Buno I, Cervera JV, Montes-Moreno S, Hernandez-Rivas JM, Ayala R, Calasanz MJ, Larrayoz MJ, Brichs LF, Gonzalez-Vicent M, Pisano DG, Piris MA, Alvarez S, Cigudosa JC (2014) Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia 28:823–829CrossRefPubMed Menezes J, Acquadro F, Wiseman M, Gomez-Lopez G, Salgado RN, Talavera-Casanas JG, Buno I, Cervera JV, Montes-Moreno S, Hernandez-Rivas JM, Ayala R, Calasanz MJ, Larrayoz MJ, Brichs LF, Gonzalez-Vicent M, Pisano DG, Piris MA, Alvarez S, Cigudosa JC (2014) Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia 28:823–829CrossRefPubMed
62.
Zurück zum Zitat Stenzinger A, Endris V, Pfarr N, Andrulis M, Johrens K, Klauschen F, Siebolts U, Wolf T, Koch PS, Schulz M, Hartschuh W, Goerdt S, Lennerz JK, Wickenhauser C, Klapper W, Anagnostopoulos I, Weichert W (2014) Targeted ultra-deep sequencing reveals recurrent and mutually exclusive mutations of cancer genes in blastic plasmacytoid dendritic cell neoplasm. Oncotarget 5:6404–6413CrossRefPubMedPubMedCentral Stenzinger A, Endris V, Pfarr N, Andrulis M, Johrens K, Klauschen F, Siebolts U, Wolf T, Koch PS, Schulz M, Hartschuh W, Goerdt S, Lennerz JK, Wickenhauser C, Klapper W, Anagnostopoulos I, Weichert W (2014) Targeted ultra-deep sequencing reveals recurrent and mutually exclusive mutations of cancer genes in blastic plasmacytoid dendritic cell neoplasm. Oncotarget 5:6404–6413CrossRefPubMedPubMedCentral
63.
Zurück zum Zitat Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, Davies H, Jones D, Lin ML, Teague J, Bignell G, Butler A, Cho J, Dalgliesh GL, Galappaththige D, Greenman C, Hardy C, Jia M, Latimer C, Lau KW, Marshall J, McLaren S, Menzies A, Mudie L, Stebbings L, Largaespada DA, Wessels LF, Richard S, Kahnoski RJ, Anema J, Tuveson DA, Perez-Mancera PA, Mustonen V, Fischer A, Adams DJ, Rust A, Chan-on W, Subimerb C, Dykema K, Furge K, Campbell PJ, Teh BT, Stratton MR, Futreal PA (2011) Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469:539–542CrossRefPubMedPubMedCentral Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, Davies H, Jones D, Lin ML, Teague J, Bignell G, Butler A, Cho J, Dalgliesh GL, Galappaththige D, Greenman C, Hardy C, Jia M, Latimer C, Lau KW, Marshall J, McLaren S, Menzies A, Mudie L, Stebbings L, Largaespada DA, Wessels LF, Richard S, Kahnoski RJ, Anema J, Tuveson DA, Perez-Mancera PA, Mustonen V, Fischer A, Adams DJ, Rust A, Chan-on W, Subimerb C, Dykema K, Furge K, Campbell PJ, Teh BT, Stratton MR, Futreal PA (2011) Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469:539–542CrossRefPubMedPubMedCentral
64.
Zurück zum Zitat Sapienza MR, Fuligni F, Agostinelli C, Tripodo C, Righi S, Laginestra MA, Pileri A Jr, Mancini M, Rossi M, Ricci F, Gazzola A, Melle F, Mannu C, Ulbar F, Arpinati M, Paulli M, Maeda T, Gibellini D, Pagano L, Pimpinelli N, Santucci M, Cerroni L, Croce CM, Facchetti F, Piccaluga PP, Pileri SA (2014) Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition. Leukemia 28:1606–1616CrossRefPubMedPubMedCentral Sapienza MR, Fuligni F, Agostinelli C, Tripodo C, Righi S, Laginestra MA, Pileri A Jr, Mancini M, Rossi M, Ricci F, Gazzola A, Melle F, Mannu C, Ulbar F, Arpinati M, Paulli M, Maeda T, Gibellini D, Pagano L, Pimpinelli N, Santucci M, Cerroni L, Croce CM, Facchetti F, Piccaluga PP, Pileri SA (2014) Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition. Leukemia 28:1606–1616CrossRefPubMedPubMedCentral
65.
Zurück zum Zitat Dalle S, Beylot-Barry M, Bagot M, Lipsker D, Machet L, Joly P, Dompmartin A, d'Incan M, Maubec E, Grange F, Dereure O, Prey S, Barete S, Wetterwald M, Fraitag S, Petrella T (2010) Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol 162:74–79CrossRefPubMed Dalle S, Beylot-Barry M, Bagot M, Lipsker D, Machet L, Joly P, Dompmartin A, d'Incan M, Maubec E, Grange F, Dereure O, Prey S, Barete S, Wetterwald M, Fraitag S, Petrella T (2010) Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol 162:74–79CrossRefPubMed
66.
Zurück zum Zitat Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, Lunghi M, Pica G, Onida F, Cattaneo C, Piccaluga PP, Di Bona E, Todisco E, Musto P, Spadea A, D'Arco A, Pileri S, Leone G, Amadori S, Facchetti F (2013) Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica 98:239–246CrossRefPubMedPubMedCentral Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, Lunghi M, Pica G, Onida F, Cattaneo C, Piccaluga PP, Di Bona E, Todisco E, Musto P, Spadea A, D'Arco A, Pileri S, Leone G, Amadori S, Facchetti F (2013) Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica 98:239–246CrossRefPubMedPubMedCentral
67.
Zurück zum Zitat Montero J, Stephansky J, Cai T, Griffin GK, Cabal-Hierro L, Togami K, Hogdal LJ, Galinsky I, Morgan EA, Aster JC, Davids MS, LeBoeuf NR, Stone RM, Konopleva M, Pemmaraju N, Letai A, Lane AA (2016) Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax. Cancer Discov 7:156–164CrossRefPubMedPubMedCentral Montero J, Stephansky J, Cai T, Griffin GK, Cabal-Hierro L, Togami K, Hogdal LJ, Galinsky I, Morgan EA, Aster JC, Davids MS, LeBoeuf NR, Stone RM, Konopleva M, Pemmaraju N, Letai A, Lane AA (2016) Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax. Cancer Discov 7:156–164CrossRefPubMedPubMedCentral
68.
Zurück zum Zitat Geissmann F, Lepelletier Y, Fraitag S, Valladeau J, Bodemer C, Debre M, Leborgne M, Saeland S, Brousse N (2001) Differentiation of Langerhans cells in Langerhans cell histiocytosis. Blood 97:1241–1248CrossRefPubMed Geissmann F, Lepelletier Y, Fraitag S, Valladeau J, Bodemer C, Debre M, Leborgne M, Saeland S, Brousse N (2001) Differentiation of Langerhans cells in Langerhans cell histiocytosis. Blood 97:1241–1248CrossRefPubMed
69.
Zurück zum Zitat Redd L, Schmelz M, Burack WR, Cook JR, Day AW, Rimsza LM (2016) Langerhans cell histiocytosis shows distinct cytoplasmic expression of major histocompatibility class II antigens. J Hamatopathol:107–112 Redd L, Schmelz M, Burack WR, Cook JR, Day AW, Rimsza LM (2016) Langerhans cell histiocytosis shows distinct cytoplasmic expression of major histocompatibility class II antigens. J Hamatopathol:107–112
70.
Zurück zum Zitat Paulli M, Locatelli F, Kindl S, Boveri E, Facchetti F, Porta F, Rosso R, Nespoli L, Magrini U (1992) Sinus histiocytosis with massive lymphoadenopathy (Rosai-Dorfman disease). Clinico-pathological analysis of a paediatric case. Eur J Pediatr 151:672–675CrossRefPubMed Paulli M, Locatelli F, Kindl S, Boveri E, Facchetti F, Porta F, Rosso R, Nespoli L, Magrini U (1992) Sinus histiocytosis with massive lymphoadenopathy (Rosai-Dorfman disease). Clinico-pathological analysis of a paediatric case. Eur J Pediatr 151:672–675CrossRefPubMed
71.
Zurück zum Zitat Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, Pusch S, Mechtersheimer G, Zentgraf H, von Deimling A (2011) Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 122:11–19CrossRefPubMed Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, Pusch S, Mechtersheimer G, Zentgraf H, von Deimling A (2011) Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 122:11–19CrossRefPubMed
72.
Zurück zum Zitat Roden AC, Hu X, Kip S, Parrilla Castellar ER, Rumilla KM, Vrana JA, Vassallo R, Ryu JH, Yi ES (2014) BRAF V600E expression in Langerhans cell histiocytosis: clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases. Am J Surg Pathol 38:548–551CrossRefPubMed Roden AC, Hu X, Kip S, Parrilla Castellar ER, Rumilla KM, Vrana JA, Vassallo R, Ryu JH, Yi ES (2014) BRAF V600E expression in Langerhans cell histiocytosis: clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases. Am J Surg Pathol 38:548–551CrossRefPubMed
73.
Zurück zum Zitat Alayed K, Medeiros LJ, Patel KP, Zuo Z, Li S, Verma S, Galbincea J, Cason RC, Luthra R, Yin CC (2016) BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases. Hum Pathol 52:61–67CrossRefPubMed Alayed K, Medeiros LJ, Patel KP, Zuo Z, Li S, Verma S, Galbincea J, Cason RC, Luthra R, Yin CC (2016) BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases. Hum Pathol 52:61–67CrossRefPubMed
74.
Zurück zum Zitat Ritterhouse LL, Barletta JA (2015) BRAF V600E mutation-specific antibody: a review. Semin Diagn Pathol 32:400–408CrossRefPubMed Ritterhouse LL, Barletta JA (2015) BRAF V600E mutation-specific antibody: a review. Semin Diagn Pathol 32:400–408CrossRefPubMed
75.
Zurück zum Zitat Neumann MP, Frizzera G (1986) The coexistence of Langerhans’ cell granulomatosis and malignant lymphoma may take different forms: report of seven cases with a review of the literature. Hum Pathol 17:1060–1065CrossRefPubMed Neumann MP, Frizzera G (1986) The coexistence of Langerhans’ cell granulomatosis and malignant lymphoma may take different forms: report of seven cases with a review of the literature. Hum Pathol 17:1060–1065CrossRefPubMed
76.
Zurück zum Zitat Egeler RM, Neglia JP, Puccetti DM, Brennan CA, Nesbit ME (1993) Association of Langerhans cell histiocytosis with malignant neoplasms. Cancer 71:865–873CrossRefPubMed Egeler RM, Neglia JP, Puccetti DM, Brennan CA, Nesbit ME (1993) Association of Langerhans cell histiocytosis with malignant neoplasms. Cancer 71:865–873CrossRefPubMed
77.
Zurück zum Zitat Vasef MA, Zaatari GS, Chan WC, Sun NC, Weiss LM, Brynes RK (1995) Dendritic cell tumors associated with low-grade B-cell malignancies. Report of three cases. Am J Clin Pathol 104:696–701CrossRefPubMed Vasef MA, Zaatari GS, Chan WC, Sun NC, Weiss LM, Brynes RK (1995) Dendritic cell tumors associated with low-grade B-cell malignancies. Report of three cases. Am J Clin Pathol 104:696–701CrossRefPubMed
78.
Zurück zum Zitat Trebo MM, Attarbaschi A, Mann G, Minkov M, Kornmuller R, Gadner H (2005) Histiocytosis following T-acute lymphoblastic leukemia: a BFM study. Leuk Lymphoma 46:1735–1741CrossRefPubMed Trebo MM, Attarbaschi A, Mann G, Minkov M, Kornmuller R, Gadner H (2005) Histiocytosis following T-acute lymphoblastic leukemia: a BFM study. Leuk Lymphoma 46:1735–1741CrossRefPubMed
79.
Zurück zum Zitat Christie LJ, Evans AT, Bray SE, Smith ME, Kernohan NM, Levison DA, Goodlad JR (2006) Lesions resembling Langerhans cell histiocytosis in association with other lymphoproliferative disorders: a reactive or neoplastic phenomenon? Hum Pathol 37:32–39CrossRefPubMed Christie LJ, Evans AT, Bray SE, Smith ME, Kernohan NM, Levison DA, Goodlad JR (2006) Lesions resembling Langerhans cell histiocytosis in association with other lymphoproliferative disorders: a reactive or neoplastic phenomenon? Hum Pathol 37:32–39CrossRefPubMed
80.
Zurück zum Zitat Shao H, Xi L, Raffeld M, Feldman AL, Ketterling RP, Knudson R, Rodriguez-Canales J, Hanson J, Pittaluga S, Jaffe ES (2011) Clonally related histiocytic/dendritic cell sarcoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a study of seven cases. Mod Pathol 24:1421–1432CrossRefPubMedPubMedCentral Shao H, Xi L, Raffeld M, Feldman AL, Ketterling RP, Knudson R, Rodriguez-Canales J, Hanson J, Pittaluga S, Jaffe ES (2011) Clonally related histiocytic/dendritic cell sarcoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a study of seven cases. Mod Pathol 24:1421–1432CrossRefPubMedPubMedCentral
81.
Zurück zum Zitat Feldman AL (2013) Clonal relationships between malignant lymphomas and histiocytic/dendritic cell tumors. Surg Pathol Clin 6:619–629CrossRefPubMed Feldman AL (2013) Clonal relationships between malignant lymphomas and histiocytic/dendritic cell tumors. Surg Pathol Clin 6:619–629CrossRefPubMed
82.
Zurück zum Zitat Ambrosio MR, De Falco G, Rocca BJ, Barone A, Amato T, Bellan C, Lazzi S, Leoncini L (2015) Langerhans cell sarcoma following marginal zone lymphoma: expanding the knowledge on mature B cell plasticity. Virchows Arch 467:471–480CrossRefPubMed Ambrosio MR, De Falco G, Rocca BJ, Barone A, Amato T, Bellan C, Lazzi S, Leoncini L (2015) Langerhans cell sarcoma following marginal zone lymphoma: expanding the knowledge on mature B cell plasticity. Virchows Arch 467:471–480CrossRefPubMed
83.
Zurück zum Zitat Benharroch D, Guterman G, Levy I, Shaco-Levy R (2010) High content of Langerhans cells in malignant lymphoma—incidence and significance. Virchows Arch 457:63–67CrossRefPubMed Benharroch D, Guterman G, Levy I, Shaco-Levy R (2010) High content of Langerhans cells in malignant lymphoma—incidence and significance. Virchows Arch 457:63–67CrossRefPubMed
84.
Zurück zum Zitat Chen W, Jaffe R, Zhang L, Hill C, Block AM, Sait S, Song B, Liu Y, Cai D (2013) Langerhans cell sarcoma arising from chronic lymphocytic lymphoma/small lymphocytic leukemia: lineage analysis and BRAF V600E mutation study. N Am J Med Sci 5:386–391CrossRefPubMedPubMedCentral Chen W, Jaffe R, Zhang L, Hill C, Block AM, Sait S, Song B, Liu Y, Cai D (2013) Langerhans cell sarcoma arising from chronic lymphocytic lymphoma/small lymphocytic leukemia: lineage analysis and BRAF V600E mutation study. N Am J Med Sci 5:386–391CrossRefPubMedPubMedCentral
85.
Zurück zum Zitat Alten J, Klapper W, Leuschner I, Eckert C, Beier R, Vallo E, Krause M, Claviez A, Vieth S, Bleckmann K, Moricke A, Schrappe M, Cario G (2015) Secondary histiocytic sarcoma may cause apparent persistence or recurrence of minimal residual disease in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 62:1656–1660CrossRefPubMed Alten J, Klapper W, Leuschner I, Eckert C, Beier R, Vallo E, Krause M, Claviez A, Vieth S, Bleckmann K, Moricke A, Schrappe M, Cario G (2015) Secondary histiocytic sarcoma may cause apparent persistence or recurrence of minimal residual disease in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 62:1656–1660CrossRefPubMed
86.
Zurück zum Zitat Fernandez-Pol S, Bangs CD, Cherry A, Arber DA, Gratzinger D (2016) Two cases of histiocytic sarcoma with BCL2 translocations and occult or subsequent follicular lymphoma. Hum Pathol 55:39–43CrossRefPubMed Fernandez-Pol S, Bangs CD, Cherry A, Arber DA, Gratzinger D (2016) Two cases of histiocytic sarcoma with BCL2 translocations and occult or subsequent follicular lymphoma. Hum Pathol 55:39–43CrossRefPubMed
87.
Zurück zum Zitat Xie H, Ye M, Feng R, Graf T (2004) Stepwise reprogramming of B cells into macrophages. Cell 117:663–676CrossRefPubMed Xie H, Ye M, Feng R, Graf T (2004) Stepwise reprogramming of B cells into macrophages. Cell 117:663–676CrossRefPubMed
88.
Zurück zum Zitat Ansari J, Naqash AR, Munker R, El-Osta H, Master S, Cotelingam JD, Griffiths E, Greer AH, Yin H, Peddi P, Shackelford RE (2016) Histiocytic sarcoma as a secondary malignancy: pathobiology, diagnosis, and treatment. Eur J Haematol 97:9–16CrossRefPubMed Ansari J, Naqash AR, Munker R, El-Osta H, Master S, Cotelingam JD, Griffiths E, Greer AH, Yin H, Peddi P, Shackelford RE (2016) Histiocytic sarcoma as a secondary malignancy: pathobiology, diagnosis, and treatment. Eur J Haematol 97:9–16CrossRefPubMed
89.
Zurück zum Zitat Michonneau D, Kaltenbach S, Derrieux C, Trinquand A, Brouzes C, Gibault L, North MO, Delarue R, Varet B, Emile JF, Brousse N, Hermine O (2014) BRAF (V600E) mutation in a histiocytic sarcoma arising from hairy cell leukemia. J Clin Oncol 32:e117–e121CrossRefPubMed Michonneau D, Kaltenbach S, Derrieux C, Trinquand A, Brouzes C, Gibault L, North MO, Delarue R, Varet B, Emile JF, Brousse N, Hermine O (2014) BRAF (V600E) mutation in a histiocytic sarcoma arising from hairy cell leukemia. J Clin Oncol 32:e117–e121CrossRefPubMed
90.
Zurück zum Zitat Huang W, Qiu T, Zeng L, Zheng B, Ying J, Feng X (2016) High frequency of clonal IG and T-cell receptor gene rearrangements in histiocytic and dendritic cell neoplasms. Oncotarget 7:78355–78362PubMedPubMedCentral Huang W, Qiu T, Zeng L, Zheng B, Ying J, Feng X (2016) High frequency of clonal IG and T-cell receptor gene rearrangements in histiocytic and dendritic cell neoplasms. Oncotarget 7:78355–78362PubMedPubMedCentral
Metadaten
Titel
Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases
verfasst von
Fabio Facchetti
Stefano Aldo Pileri
Luisa Lorenzi
Valentina Tabanelli
Lisa Rimsza
Stefania Pittaluga
Stephan Dirnhofer
Christiane Copie-Bergman
Laurence de Leval
Andreas Rosenwald
Andrew Wotherspoon
Falko Fend
Publikationsdatum
10.07.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Virchows Archiv / Ausgabe 4/2017
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-017-2176-1

Weitere Artikel der Ausgabe 4/2017

Virchows Archiv 4/2017 Zur Ausgabe

Neu im Fachgebiet Pathologie